<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552730</url>
  </required_header>
  <id_info>
    <org_study_id>57888</org_study_id>
    <nct_id>NCT04552730</nct_id>
  </id_info>
  <brief_title>Nerve Growth Factor for the Treatment of Cornea Disease</brief_title>
  <official_title>Observational Study of Cenegermin-bkbj in the Treatment of Limbal Stem Cell Deficiency Associated With Neurotrophic Keratopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem&#xD;
      cell deficiency (LSCD) associated with neurotrophic cornea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective open-label pilot study evaluating the role of cenegermin-bkbj for the&#xD;
      treatment of LSCD with associated neurotrophic keratopathy. Patient diagnosed with LSCD with&#xD;
      neurotrophic cornea who have failed conventional treatment such as artificial tears are&#xD;
      enrolled in the study after a 2 week washout period. Patient are then treated with&#xD;
      cenegermin-bkbj over an 8 week period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Size of abnormal epithelium</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Change in size of abnormal epithelium compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with resolution of epithelial defect if present prior to treatment</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Number of patients with resolution of epithelial defect if present prior to treatment (Stage 2) Mackie Classification of neurotrophic cornea at time of enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cornea sensation</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Cornea sensation measured with Cochet-Bonnet aesthesiometer after treatment compared to screening visit.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Neurotrophic Keratitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenegermin-Bkbj</intervention_name>
    <description>Topical Cenegermin-bkbj 6 times per day for 8 weeks.</description>
    <other_name>Oxervate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults. Both sexes will be recruited. Any ethnic background, as long as they meet the&#xD;
        inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients diagnosed with LSCD and neurotrophic cornea confirmed by testing with&#xD;
        Cochet-Bonnet aesthesiometer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active ocular infection&#xD;
&#xD;
          2. Anticipated need for bandage contact lens, amniotic membrane graft, or tarsorrhaphy&#xD;
             during the study period&#xD;
&#xD;
          3. Unable to discontinue the use of contact lens&#xD;
&#xD;
          4. Visual acuity worse than 20/200 in the better eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher N Ta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Christopher Ta</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

